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Background. Optimal treatment of nongastrointestinal stromal tumor soft-tissuesarcomas (non-GIST STSs) is resection with wide
margins. This study investigates the prognostic impact of the angiogenesis-associated platelet-derived growth factors (PDGFs)
and their receptors (PDGFRs) in non-GIST STS patients with wide and nonwide resection margins. Method. Tumor samples and
clinical data from 249 patients with non-GIST STS were obtained, and tissue microarrays were constructed for each specimen.
Immunohistochemistry was used to evaluate the expression of PDGF-A, -B, -C, and -D and PDGFR-α and -β. Results.I nt h e
multivariate analysis of patients with wide resection margins, high expression of PDGF-B (P = .013, HR = 2.954, and 95% CI =
1.255–6.956) and the coexpression of PDGF-B and PDGFR-α (overall; P = .016, high-low/low-high; P = .051, HR = 2.678, 95%
CI = 0.996–7.200, high/high; P = .004, HR = 3.930, 95% CI = 1.542–10.015) were independent negative prognostic markers
for disease-speciﬁc survival. Conclusion. PDGF-B and the coexpression of PDGF-B and PDGFR-α are strong and independent
prognostic factors in non-GIST STSs with wide resection margins.
1.Introduction
Soft-tissue sarcomas (STSs) are mesenchymal-derived tu-
mors comprising about 0.5% of the annual cancer incidence
with an estimate of ten thousand new patients and nearly
four thousand related deaths in the USA in 2009 [1]. The
STS group consists of more than 50 histological entities
[2]. Because of the low incidence and similar ancestry
of these tumors it is convenient to group them together
when conducting studies [2, 3]. A proposed way to group
these tumors is Ewing family tumors, gastrointestinal stro-
mal tumors (GISTs), and non-GIST STSs, with the latter
group consisting of the remaining tumors [3]. Despite
improvements in therapy over the last decades the disease-
speciﬁc survival (DSS) and progression-free survival (PFS)
of sarcoma patients are still poor. The main treatment is
resection with wide margins, while radiotherapy is often
used in high-grade tumors with both marginal and wide
resection margins [4, 5]. Even when wide resection margins
are obtained, a relatively high proportion of patients die
[6, 7]. Several adjuvant chemotherapy-regimes are used
for the treatment of sarcomas, but with the exception of
childhood rhabdomyosarcomas, Ewing family tumors and
GISTs, studies are inconclusive on the eﬀects of these agents
[4,8,9].Identiﬁcationofthesubgroupofpatients,withwide
resection margins and low survival, could prove important,
as these patients might beneﬁt from adjuvant therapy.
The platelet-derived growth factor (PDGF) group of sig-
naling molecules consists of four proteins forming ﬁve possi-
ble ligands in vivo, namely PDGF-AA, PDGF-AB, PDGF-BB,2 Sarcoma
PDGF-CC, and PDGF-DD [10]. The platelet-derived growth
factor receptors (PDGFRs) are structurally related tyrosine-
kinase receptors consisting of either α-o rβ-chains forming
three possible receptors: PDGFR-αα, PDGFR-αβ,a n d
PDGFR-ββ. The PDGF-AA binds exclusively to the PDGFR-
αα, while PDGF-AB and -CC bind to both the PDGFR-αα
and PDGFR-αβ; PDGF-DD binds both PDGFR-αβ and
PDGFR-ββ, while PDGF-BB binds all PDGFRs [10].
PDGFs and PDGFRs play a major role in angiogenesis,
the recruitment and regulation of tumor stroma, and the
regulation of tumor interstitial ﬂuid pressure (IFP) [11].
In addition PDGFs have been shown to function as pow-
erful transforming growth factors, leading cells to progress
through cell-cycle and avoid apoptosis [12].
The PDGF/PDGFR pathways have previously been im-
plicated in several sarcomas including GIST, dermatoﬁ-
brosarcoma protuberans, childhood rhabdomyosarcoma,
Kaposis sarcoma, osteosarcoma, and Ewing family sarcoma
[11, 13–19]. Regarding non-GIST STSs, there are no con-
clusive studies on the prognostic impact of PDGF/PDGFRs.
Knowledge about the expression and prognostic impact
of PDGFs and PDGFRs may be important in identifying
patients with wide resection margins and low DSS. With the
emerging class of selective small molecule inhibitors target-
ingthesepathways,thismightbeparticularlyimportant.The
study presented herein investigates the prognostic impact
of PDGFs and PDGFRs in non-GIST STS with wide and
nonwide resection margins.
2. Patientsand Methods
2.1. Patients and Clinical Samples. Primary tumor tissue
from anonymized patients diagnosed with non-GIST STS at
the University Hospital of North Norway and the hospitals
of Arkhangelsk county, Russia, from 1973 through 2006,
were collected. In total, 496 patients were registered from
the hospital databases. Of these 247 patients were excluded
from the study because of missing clinical data (n = 86) or
inadequate paraﬃn-embedded ﬁxed tissue blocks (n = 161).
Thus, 249 patients with complete medical records and
adequate paraﬃn-embedded tissue blocks were eligible.
This report includes followup data as of September 2009.
The median followup was 37.6 (range 0.1–391.7) months.
Complete demographic and clinical data were collected ret-
rospectively. Formalin-ﬁxed and paraﬃn-embedded tumor
specimens were obtained from the archives of the Depart-
ments of Pathology at the University Hospital of North
Norway and the hospitals of Arkhangelsk county, Russia.
The tumors were graded according to the French F´ ed´ eration
Nationale des Centres de Lutte Contre le Cancer (FNCLCC)
system and histologically subtyped according to the World
Health Organization guidelines [2, 20]. Wide resection
margins were deﬁned as wide local resection with free
microscopic margins or amputation of the aﬀected limb or
organ. Nonwide resection margins were deﬁned as marginal
or intralesional resection margins, or no surgery.
2.2. Microarray Construction. A l ls a r c o m a sw e r eh i s t o l o g i -
cally reviewed by two trained pathologists (S. Sorbye and
A. Valkov), and the most representative areas of tumor
cells (neoplastic mesenchymal cells) were carefully selected
and marked on the hematoxylin and eosin (H/E) slide
and sampled for the tissue microarray (TMA) blocks. The
TMAs were assembled using a tissue-arraying instrument
(Beecher Instruments, Silver Springs, MD, USA). The
detailed methodology has been previously reported in [21].
Brieﬂy, we used a 0.6mm diameter stylet, and the study
specimens were routinely sampled with four replicate core
samples from diﬀerent areas of neoplastic tissue. Normal
tissue from the patients was used as staining control.
To include all core samples, 12 TMA blocks were
constructed. Multiple 5-μm sections were cut with a Micron
microtome (HM355S) and stained by speciﬁc antibodies for
immunohistochemistry (IHC) analysis.
2.3. Immunohistochemistry. The applied antibodies were
subjected to in-house validation by the manufacturer for
IHC analysis on paraﬃn-embedded material. The antibodies
usedinthestudywereasfollows:PDGF-AA(goatpolyclonal;
AB-221-NA; R&D Systems; 1:200), PDGF-AB/BB (rabbit
polyclonal; RB-9257; Neomarkers; 1:15), PDGF-CC (goat
polyclonal; GT15151; Neuromics; 1:80), PDGF-DD (goat
polyclonal;AF1159;R&DSystems;1:400),PDGFR-α(rabbit
polyclonal; RB-9027; Neomarkers; 1:75), and PDGFR-β
(rabbit polyclonal; RB-9032; Neomarkers; 1:25).
Sections were deparaﬃnized with xylene and rehydrated
with ethanol. Antigen retrieval of PDGF-A, -B, -C, and
-D was performed by placing the specimen in 0.01M
citrate buﬀer at pH 6.0 and exposing them to repeated
(×2) microwave heating of 10min at 450W. PDGF-A,
-B, and -C were stained using peroxydase/DAB (Dako
EnVision+System-HRP/DAB). The primary antibodies were
incubated for 30min in room temperature. PDGF-D was
visualized by adding a secondary antibody conjugated with
Biotin, followed by an Avidin/Biotin/Peroxydase complex
(Vectastein ABC Elite kit from Vector Laboratories). The
primary antibody was incubated overnight at 4◦C. Finally, all
slides were counterstained with hematoxylin to visualize the
nuclei.
The receptors (PDGFR-α and -β) were stained using
Ventana BenchMark XT (Ventana Medical Systems Inc.),
procedure iView DAB. Antigen retrieval was done in
Tris/EDTA buﬀer at pH 8.4 for 30min (PDGFR-α)o r6 0m i n
(PDGFR-β)a t3 7 ◦C. The primary antibodies were incubated
for 30min in room temperature.
Foreachantibody,includednegativestainingcontrols,all
TMA stainings were done in a single experiment.
2.4. Scoring of Immunohistochemistry. The ARIOL imaging
system (Genetix, San Jose, CA) was used to scan the slides
of antibody staining of the TMAs. The slides were loaded
in the automated slide loader (Applied Imaging SL 50), and
the specimens were scanned at low resolution (1.25×)a n d
high resolution (20x) using the Olympus BX 61 microscope
with an automated platform (Prior). Representative and
viable tissue sections were scored manually on computer
screensemiquantitativelyforcytoplasmicstaining.Thedom-
inant staining intensity was scored as 0: negative, 1: weak,Sarcoma 3
(a) (b)
(c) (d)
Figure 1: IHC analysis of TMA of nongastrointestinal stromal tumor soft-tissue sarcoma representing diﬀerent scores for tumor cell PDGF-
Ba n dP D G F R - α. (a) Tumor cell PDGF-B high score; (b) tumor cell PDGF-B low score; (c) tumor cell PDGFR-α high score; (d) tumor cell
PDGFR-α low score. Abbreviations: IHC: immunohistochemistry; TMA: tissue microarray; PDGF: platelet-derived growth factor; PDGFR:
platelet-derived growth factor receptor.
2: intermediate, and 3: strong. All samples were anonymized
and independently scored by two trained pathologists
(A. Valkov and S. Sorbye). When assessing a variable for a
given core, the observers were blinded to the scores of the
other variables and to the outcome. Mean score for duplicate
cores from each individual was calculated separately.
High expression in tumor cells was deﬁned as score
≥1.5 (PDGF-A, PDGF-C, and PDGF-B) and ≥2 (PDGF-D,
PDGFR-α, and PDGFR-β)( Figure 1).
2.5. Statistical Methods. All statistical analyses were done
usingthestatisticalpackageSPSS(Chicago,IL,USA),version
16. The IHC scores from each observer were compared for
interobserver reliability by use of a two-way random
eﬀect model with absolute agreement deﬁnition. The
intraclass correlation coeﬃcient (reliability coeﬃcient) was
obtained from these results. The Chi-square test and Fishers
Exact test were used to examine the association between
molecularmarkerexpressionandvariousclinicopathological
parameters. Univariate analyses were done using the
Kaplan-Meier method, and statistical signiﬁcance between
survival curves was assessed by the log-rank test. DSS
was determined from the date of diagnosis to the time of
cancer-related death. To assess the independent value of
diﬀerent pretreatment variables on survival, in the presence
of other variables, multivariate analyses were carried out
using the Cox proportional hazards model. Only variables of
signiﬁcant value from the univariate analyses were entered
into the Cox regression analyses. Probability for stepwise
entry and removal was set at.05 and.10, respectively. The
signiﬁcance level used for all statistical tests was P<. 05.
2.6. Ethical Clearance. The National Data Inspection Board
and The Regional Committee for Research Ethics approved
the study.
3. Results
3.1. Clinopathological Variables. The clinopathological vari-
ables are summarized in Table 1. The median age was 594 Sarcoma
Table 1: Prognostic clinicopathological variables as predictors for disease-speciﬁc survival in 249 nongastrointestinal stromal tumor soft-
tissue sarcomas (univariate analyses; log-rank test).
Characteristics Patients (n) Patients (%) Median survival (months) 5-year survival (%) P
Age
≤20 years 20 8 15 40 .126
21–60 years 113 45 68 52
>60 years 116 47 30 40
Gender
Male 110 44 41 46 .390
Female 139 56 45 45
Patient nationality
Norwegian 167 67 63 51 .011
Russian 82 33 22 34
Histological entity
Pleomorphic sarcoma 58 23 54 47 .001
Leiomyosarcoma 64 26 48 48
Liposarcoma 34 14 NR 67
Fibrosarcoma 20 8 44 50
Angiosarcoma 13 5 10 31
Rhabdomyosarcoma 16 6 17 38
MPNST 11 4 49 45
Synovial sarcoma 16 6 31 29
Sarcoma NOS 17 7 9 18
Tumor localization
Extremities 89 36 100 53 .348
Trunk 47 29 32 44
Retroperitoneum 37 25 25 38
Head/neck 18 7 15 41
Visceral 58 23 30 42
Tumor size
≤5 cm 74 30 127 57 .027
5–10cm 91 37 44 45
>10cm 81 32 28 37
Missing 3 1
Malignancy grade
16 1 2 5 N R 7 4 <.001
29 8 3 9 4 1 4 5
39 0 3 6 1 6 2 6
Tumor depth
Superﬁcial 17 7 NR 93 <.001
Deep 232 93 36 42
Metastasis at diagnosis
No 206 83 76 53 <.001
Yes 43 17 10 10
Surgery
Yes 228 91 59 50 <.001
No 21 9 4 0
Resection margins
Wide 108 43 NR 62 <.001
Nonwide/no surgery 141 57 21 33
Chemotherapy
No 191 77 52 47 .424
Yes 58 23 29 40
Radiotherapy
No 176 71 48 46 .590
Yes 73 29 38 43
Abbreviations: NR: not reached; MPNST: malignant peripheral nerve sheath tumor; NOS: not otherwise speciﬁed.Sarcoma 5
(range 0–91) years, 56% were female; 167 patients were
Norwegian and 82 Russian. The Non-GIST STSs comprised
249 tumors including angiosarcoma (n = 13), ﬁbrosar-
coma (n = 20), leiomyosarcoma (n = 64), liposarcoma
(n = 34), pleomorphic sarcoma (n = 58), neuroﬁbrosar-
coma/malignant peripheral nerve sheath tumor (MPNST,
n = 11), rhabdomyosarcoma (n = 16), synovial sarcoma
(n = 16), and unspeciﬁed sarcoma (n = 17). The
tumor origins were distributed as follows: 36% extremities,
19% trunk, 15% retroperitoneal, 7% head/neck, and 23%
visceral. Of 228 patients who underwent surgery, 53%
received surgery alone, 24% surgery and radiotherapy, 18%
surgery and chemotherapy, and 6% surgery, radiotherapy,
and chemotherapy. Besides, 21 patients did not undergo
surgery due to inoperable tumor (n = 11), high age/other
serious diseases (n = 5), STS conﬁrmed at autopsy (n = 3)
and patient refusal (n = 2). Of these unresected patients,
seven patients received chemotherapy and/or radiotherapy,
whereas 14 patients received no anticancer therapy.
3.2. Interobserver Variability. Interobserver scoring agree-
ment was tested for one ligand (PDGF-B) and one receptor
(PDFGR-α). The intraclass correlation coeﬃcients were
0.890 for PDGF-B (P<. 001) and 0.892 for PDFGR-α
(P<. 001) indicating good reproducibility between the two
investigating pathologists.
3.3. Expression of PDGFs/PDGFRs and Their Correlations.
PDGF/PDGFR-expression was observed in the cytoplasm
of tumor cells. No correlation was seen between increased
tumor PDGF/PDGFR expression and tumor depth, surgery,
radiotherapy, or chemotherapy. Among the most interesting
correlations, PDGFR-α correlated with malignancy grade
(high expression; grade 1: 25%, grade 2: 39%, grade 3:
54%, P = .003) and PDGFR-β was more often expressed
in patients with metastasis at diagnosis (35%, versus no
metastasis at diagnosis, 18%, P = .015).
3.4. Univariate Analyses. Among demographic and clinico-
pathological variables in the total material, patient nation-
ality (P = .011), histological entity (P = .001), tumor size
(P = .027), malignancy grade (P<. 001), tumor depth (P<
.001), metastasis at diagnosis (P<. 001), surgery (P<. 001),
and resection margins (P<. 001) were signiﬁcant prognostic
indicators of DSS (Table 1).
In the subgroup with wide resection margins, patient
nationality (P<. 001), malignancy grade (P<. 001), tumor
depth(P = .009),andmetastasisatdiagnosis(P<. 001)were
signiﬁcant prognostic indicators of DSS. In the subgroup
with nonwide resection margins, malignancy grade (P<
.001), metastasis at diagnosis (P<. 001), surgery (P<. 001),
andhistologicalentity(P = .004) weresigniﬁcantprognostic
indicators of DSS.
The inﬂuence on DSS by the PDGFs and PDGFRs
is shown in Table 2 and Figure 2. In the total material,
high expressions of PDGFR-α (P = .004) and PDGFR-β
(P = .047) were signiﬁcant negative prognostic indicators
of DSS. In the subgroup with wide resection margins, high
expressions of PDGF-B (P = .007), PDGF-D (P = .029),
PDGFR-α (P = .001), and PDGFR-β (P = .022) were
signiﬁcant negative prognostic indicators of DSS, while in
the subgroup with nonwide resection margins none of the
PDGFs or PDGFRs were signiﬁcant indicators of DSS.
3.5. Multivariate Cox Proportional Hazards Analyses. Results
of the multivariate analyses are presented in Tables 3 and 4.
In the total material, tumor depth (P = .019), tumor size
(P = .034), high malignancy grade (P<. 001), lack of
surgery (P<. 001), nonwide resection margins (P = .013),
and metastasis at diagnosis (P<. 001) were signiﬁcant
independent prognostic indicators of DSS (Table 3). In the
subgroup with wide resection margins, Russian nationality
(P = .012), high malignancy grade (P = .005), metastasis at
diagnosis (P = .001), and high expression of PDGF-B (P =
.013, HR = 2.954, 95% CI = 1.255–6.956) were signiﬁcant
independent prognostic indicators of DSS (Table 4). In the





assess the coexpression between PDGFs and their receptors
as these can represent additive and/or synergic eﬀects on
DSS. In univariate analyses, the coexpression of PDGF-B
andPDGFR-αwasasigniﬁcantnegativeprognosticindicator
of DSS both in the total material (P = .020) and in the
subgroup with wide resection margins (P = .001). In the
latter group, the coexpression was a signiﬁcant independent
negative prognostic indicator of DSS (overall; P = .016,
intermediate; P = .051, HR = 2.678, 95% CI = 0.996–7.200,
high; P = .004, HR = 3.930, 95% CI = 1.542–10.015).
4. Discussion
The main treatment for non-GIST STSs is surgery with
wide resection margins [4]. The 5-year survival is 30% in
the group with nonwide resection margins and 60% among
those with wide resection margins. The explanation for the
modest survival, despite wide resection margins, might be
micrometastasis into the surrounding tissue, lymphogenic
regional spread, or hematogenous metastasis. Any possibility
to identify those patients who will subsequently succumb
to progression and metastasis from their resected sarcoma
within the wide resection margin group will be pivotal, as
these patients may beneﬁt from adjuvant therapy.
We present a large-scale retrospective study of the
prognostic impact of PDGF-A, -B, -C, and -D and PDGFR-α
and -β in non-GIST STS patients. High expression of PDGF-
B and the coexpression of PDGF-B and PDGFR-α were
signiﬁcant independent negative prognostic indicators of
DSS in those with wide resection margins. To our knowledge
this is the ﬁrst evaluation of PDGFs and PDGFRs in non-
GIST STSs according to resection margins [22].
The major limitation of this study consists of tumor
heterogeneity as diﬀerent types of non-GIST STS, diverse
disease sites, as well as diﬀerent therapies are included. These
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Survival (months)
Low expression, n = 32
High expression, n = 74
P = .007
PDGF-B, wide resection margins
Figure 2: Disease-speciﬁc survival curves for PDGF-B and the coexpression of PDGF-B & PDGFR-α in the overall material and in patients
with wide and nonwide resection margins. (a) PDGF-B, total material; (b) PDGF-B, wide resection margins; (c) PDGF-B, nonwide resection
margins; (d) coexpression of PDGF-B and PDGFR-α, total material; (e) coexpression of PDGF-B and PDGFR-α, wide resection margins;
(f) coexpression of PDGF-B and PDGFR-α, nonwide resection margins. Abbreviations: PDGF: platelet-derived growth factor; PDGFR:























































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































































Table 3: Result of the Cox regression analysis among all patients.
Factor Hazard ratio 95% CI P
Tumor depth
Superﬁcial 1.000
Deep 9.765 1.339–71.189 .025
Tumor size .028∗
≤5 cm 1.000
5–10cm 1.379 0.855–2.223 .187
>10cm 1.960 1.192–3.221 .008
Malignancy grade <.001∗
1 1.000
2 2.914 1.605–5.292 <.001
3 4.600 2.527–8.373 <.001
Surgery
Yes 1.000
No 8.628 4.269–17.438 <.001
Resection margins
Wide 1.000
Nonwide 1.847 1.243–2.744 .003
Metastasis at time of diagnosis
No 1.000
Yes 2.562 1.644–3.991 <.001
∗Overall signiﬁcance as a prognostic factor.
analysis. Recent studies have suggested new ways of grouping
STSs according to their mutational status in addition to
histology [22]. A homologous population with knowledge
of mutational status of common sarcoma mutations would
have been interesting, but this is diﬃcult to arrange in the
setting of a retrospective study.
The major strengths of this study lie in the size of the
cohort, the consistency of the clinical variables with previous
studies on sarcomas, and the biological soundness of our
ﬁndings.
In 1994, Wang et al. reported a positive correlation
between increased PDGF-B expression and high histological
malignancy grade of STSs using a set of 56 STSs of all grades
including benign tumors [23]. Herein, we did not observe
a correlation between PDGF-B expression and histological
grade, but PDGF-B appeared to be a signiﬁcant independent
negative prognostic marker for DSS in patients with wide
resection margins.
Experiments in mice have shown involvement of
endothelial-derived PDGF-B, in both pericyte and vascular
smooth muscle cell (VSM) recruitment and stabilization,
during blood vessel formation [24–26]. Pericytes have been
implicated in diﬀerentiation and stabilization of blood
vessels, and VSMs are an important component of blood
vessel walls. As adequate blood supply is pivotal in tumor
formation,tumor-derived PDGF-Bcouldrepresentawayfor
recruitment of pericytes and VSMs, leading to tumor growth
and increased viability and tumor forming capabilities of
metastatic tumors. High tumor interstitial ﬂuid pressure
(IFP) has been shown to lower chemotherapeutic response
due to lower transcapillary transport of chemotherapeutic
Table 4: Results of the Cox regression analysis among patients with
wide resection margins.
Factor Hazard ratio 95% CI P
Patient nationality
Norwegian 1.000
Russian 2.292 1.199–4.383 .012
Malignancy grade .005∗
1 1.000
2 4.438 1.262–15.609 .020
3 7.368 2.138–25.389 .002
Metastasis at time of diagnosis
No 1.000
Yes 3.939 1.801–8.613 .001
PDGF-B
Low 1.000
High 2.954 1.255–6.956 .013
∗Overall signiﬁcance as a prognostic factor. Abbreviations: PDGF: platelet-
derived growth factor.
agents [27]. PDGF-B has been shown to increase IFP and
mayplayaroleintumorsshowingunexpectedpoorresponse
to chemotherapy [11]. Studies in mice demonstrated that
blocking PDGFs and PDGFRs resulted in better response to
chemotherapy in several experimental tumor types [28, 29].
These ﬁndings indicate that increased expression of PDGFs
and PDGFRs might perturb the eﬀect of chemotherapy
and therefore contribute to explain why the response to
chemotherapy remains controversial in non-GIST STSs.
PDGF-B primarily signals through PDGFR-β but has also
been shown to signal through PDGFR-α [10]. Upon receptor
activation, PDGF-B has strong transforming capabilities,
activating several intracellular pathways, including PI3K,
PLCγ, SRC, and RAS. Activation of these pathways might
lead to increased cell cycling and avoidance of apoptosis
[12]. In univariate analysis, high expression of PDGF-D
was a signiﬁcant negative prognostic marker in non-GIST
STSs with wide resection margins. PDGF-D has previously
beenshowntoexhibitextensivetransformingandangiogenic
abilities [30]. Vessels formed in PDGF-D-driven tumors
show great similarity to vessels formed by PDGF-B-driven
tumors, suggesting that PDGF-D, in absence of PDGF-B, can
take over some or all of PDGF-Bs angiogenic functions [30].
Further, both PDGFR-α and -β were signiﬁcant negative
prognostic markers for non-GIST STSs with wide resection
margins. PDGFRs have been regarded as a “driving force” in
many human cancers, including GISTs, through autoactiva-
tion and constitutive signaling [19]. The fact that PDGFR-
α correlated with malignancy grade and that PDGFR-β
correlated with metastasis at diagnosis suggests that this
might also be the case in non-GIST STSs, although further
investigation is warranted.
We also found the coexpression of PDGF-B and
PDGFR-α to have a signiﬁcant independent negative prog-
nostic impact in non-GIST STS with wide resection margins.
A signiﬁcantly lower survival in the high-high group versus
the low-low and the high-low/low-high groups suggestsSarcoma 9
an additive or possibly synergic eﬀect (Figure 2). The exact
mechanism for this ﬁnding is not clear, but there are several
possible explanations. As previously mentioned, PDGF-B
preferably signals through PDGFR-β but can also signal
through PDGFR-α. When both PDGFRs and PDGF-B are
expressed in the tumor it is likely that both pathways are
simultaneously stimulated by PDGF-B or by consecutive
stimulation of the PDGFR-β with constitutively active
PDGFR-α. Part of the eﬀect might also come from PDGF-
B interactions with stromal components like pericytes and
VSMs. Simultaneous stimulation of both PDGFR axes,
together with the proposed angiogenic and stromal regula-
tory eﬀects of PDGF-B, may explain the decreased DSS in
non-GIST STS patients with wide resection margins.
Small-molecule inhibitors of tyrosine kinase receptors
have been used in the treatment of GISTs, dermatoﬁ-
brosarcoma protuberans, chronic myelogenous leukemia,
and others, demonstrating great therapeutic potential [31].
Cell line experiments and animal studies suggest syner-
gistic eﬀects and reduced side eﬀects of these inhibitory
agents together with conventional chemo- or radiotherapy
[28, 29].
5. Conclusion
Despite wide resection margins, one third of patients still
die of non-GIST STS. We have identiﬁed high expression of
PDGF-B to be an independent negative prognostic factor for
DSS in non-GIST STS patients with wide resection margins.
Further, PDGF-B and PDGFR-α coexpression revealed a
wide resection margin subgroup with particularly poor DSS.
Our results indicate involvement of PDGF and/or PDGFRs
in non-GIST STS pathogenesis. The mechanisms responsible
for this involvement have to be further elucidated and ﬁnally
validated in prospective clinical trials. With the evolving
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